



## Preparing Europe for Novel Psychedelic-Assisted Therapies

### The launch meeting of PAREA (virtual)

23<sup>rd</sup> June; 14:00 – 16:00 CEST

#### AGENDA

- 14:00**     **Welcome**  
*Prof. David Nutt, PAREA Chair*
- 14:07**     **Opening keynote address**  
*Dr Thomas R. Insel, Former Director of the US National Institute of Mental Health (2002 – 2015)\**
- 14:17**     **Opening remarks from the EU policy maker**  
*Dr Sara Cerdas, Member of the European Parliament\**
- 14:22**     **Testimonial from participant of psychedelic-assisted therapy**  
*Awakn Life Sciences case study*  
*Dave Pounds, Phase IIa trial participant – MDMA for Alcohol Use Disorder\**
- 14:30**     **Psychedelic medicines + Audience Q&A**  
*Prof. Gitte Moos Knudsen, University of Copenhagen and President of the European College of Neuropsychopharmacology*
- 14:55**     **PAREA: The Time is Now**  
*Tadeusz Hawrot, PAREA Founder and Policy Lead*
- 15:10**     **In discussion with the EU and PAREA members + Audience Q&A**  
Panel moderated by Frederic Destrebecq, PAREA Vice Chair and European Brain Council Executive Director, with:  
*European Medicines Agency: Dr Florence Butlen-Ducuing - Senior Scientific Officer, Office of Therapies for Neurological and Psychiatric Disorders*  
*European Commission: Dr Tim Raemaekers, Policy and Programme Officer, Combatting Diseases Unit, DG Research*  
*PAREA members perspectives:*  
*Patients: Jacinta Hastings, Global Alliance of Mental Illness Advocacy Networks – GAMIAN Europe*  
*Artemis Komatina, Association of European Cancer Leagues Patient Support Working Group, Cyprus Association of Cancer Patients and Friends*  
*Psychedelic foundation: Joost Breeksema, Executive Director, Open Foundation*  
*Industry: Dr. Amir Inamdar, Chief Medical Officer, Cybin*
- 15:50**     **Closing remarks and launch of a Call to Action**  
*Deirdre Ryan, PAREA Vice Chair and Pain Alliance Europe President*

\* These sections of the agenda re pre-recorded